biostudies-literatureMahil SKPsoriasis AssociationLEO Foundation Skin Immunology Research CenterManchester Biomedical Research CentreMedical Research CouncilNational Institute for Health Research (NIHR)Wellcome Trust60-71https://www.ebi.ac.uk/biostudies/studies/S-EPMC7566694biostudies-literatureUnknown147(1)<h4>Background</h4>The multimorbid burden and use of systemic immunosuppressants in people with psoriasis may confer greater risk of adverse outcomes of coronavirus disease 2019 (COVID-19), but the data are limited.<h4>Objective</h4>Our aim was to characterize the course of COVID-19 in patients with psoriasis and identify factors associated with hospitalization.<h4>Methods</h4>Clinicians reported patients with psoriasis with confirmed/suspected COVID-19 via an international registry, Psoriasis Patient Registry for Outcomes, Therapy and Epidemiology of COVID-19 Infection. Multiple logistic regression was used to assess the association between clinical and/or demographic characteristics and hospitalization. A separate patient-facing registry characterized risk-mitigating behaviors.<h4>ResultThe Journal of allergy and clinical immunologyFactors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study.PMC7566694HDR-9001Translational Skin ImmunologyPsoProtectCL-2018-06-006HDR-9006MR/T02383X/1MR/S003126/1HDR-9002Langan SMBalogh EAValenzuela FCarolan JESmith CHYiu ZZNMakrygeorgou Avan Geest AJRossi MTMarovt MDand NCesar GADe La Cruz CGenao DRCeline GVandaele MMagnano MHughes JDauden EOrtiz-Salvador JMClareus BWNaldi LLesort CGriffiths CEMMcMahon DECarras ELoayza ECummings DMercado-Seda REssex AReeken SBachelez HRustin MKerisit KGJullien DJohnston GAvan Huizen APrims CTPhan CPanchal MKlujszo EPopov GDeCrescenzo ARivera RTorres TPuig LJones ASchwartz JJMoorhead LPaolino ARomiti RKirk SPsoProtect study groupCarrascosa JMAyob SBewley AMcAteer HRomero-Mate AAsfour LLakhan MQuinlan CKhatun RBarea ASpeeckaert RBarker JNGreco CCardozo GAEidsmo LMeynell FMwale ASonkoly EGribben LSergeant ASkov LPearson ITsakok TFreeman EEVelasco MGoldsmith PMeuleman LMahe EBarclay CZargari OMackenzie TWu KMorales Callaghan AMVarela PHampton PSvensson MLLambert JPiaserico Sde Graaf LDavis CMaybury CAparicio GPerez-Barrio SToni EWeisman JDi Lernia VDesai TVHoey SMahil SKDwyer EGisondi PCarugno AFeldman SRPink AEStefanescu SRech GBrassard DMartinez AHasab VZCohen RWTaberner RFranco MDDe Caso PChoon SEMartinez-Garcia EKolli DCoker BPerez-Suarez BBak RCapon FWoolf RSingapore AJenkin PKing VJackson KMason KJYanguas ISpuls PKing GHawryluk ECeovic RDi Meglio PShah AWarren RBDescamps VFarida BTalme TKoreja ZfalseFactors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study.<h4>Background</h4>The multimorbid burden and use of systemic immunosuppressants in people with psoriasis may confer greater risk of adverse outcomes of coronavirus disease 2019 (COVID-19), but the data are limited.<h4>Objective</h4>Our aim was to characterize the course of COVID-19 in patients with psoriasis and identify factors associated with hospitalization.<h4>Methods</h4>Clinicians reported patients with psoriasis with confirmed/suspected COVID-19 via an international registry, Psoriasis Patient Registry for Outcomes, Therapy and Epidemiology of COVID-19 Infection. Multiple logistic regression was used to assess the association between clinical and/or demographic characteristics and hospitalization. A separate patient-facing registry characterized risk-mitigating behaviors.<h4>Result2021-01-01T00:00:00Z2021 Jan2025-06-01T00:49:16.19Z2021-02-21T11:38:58ZS-EPMC75666943307540810.1016/j.jaci.2020.10.007